adalimumab vs gabapentin
According to this portal's Publishing Organization, this page was last reviewed in August 2026 against our methodology. Figures and extracts on this site, including tables above 1,000 rows when the corpus is that large, are the publisher's responsibility.
Side-by-side comparison of adalimumab and gabapentin. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Humira
Neurontin, Gralise
Idacio is a medicine that blocks a protein called TNF. It is used to treat several diseases, including arthritis and Crohn's disease.
Gabapentin is a medicine that can treat nerve pain and seizures. It works by calming overactive nerves in the body.
Idacio can help adults with rheumatoid arthritis by reducing joint pain and damage. It can also help children (2 years and older) with juvenile idiopathic arthritis. Idacio treats psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa and uveitis.
Gabapentin is used to manage nerve pain after shingles in adults. This is called postherpetic neuralgia. It is also used with other medicines to treat partial seizures in adults and children ages 3 and older who have epilepsy.
Idacio works by blocking a protein in your body called tumor necrosis factor (TNF). TNF can cause inflammation and damage in certain diseases. By blocking TNF, Idacio can reduce these symptoms.
Gabapentin affects how nerves send signals to the brain. It is thought to work by decreasing the activity of overexcited nerve cells. This can reduce pain and prevent seizures.
- • Infections (like colds or sinus infections)
- • Injection site reactions (redness, itching, pain, or swelling)
- • Headache
- • Rash
- • Dizziness
- • Sleepiness
- • Swelling in arms and legs
- • Uncoordinated movements
- • Tiredness
- Pain 49,062
- Arthralgia 48,039
- Injection Site Pain 47,251
- Fatigue 39,111
- Rheumatoid Arthritis 35,573
- Fatigue 24,397
- Nausea 21,946
- Pain 20,744
- Diarrhoea 17,454
- Headache 17,287
Idacio can increase your risk of serious infections that could lead to hospitalization or death. Tell your doctor if you have any infections before starting Idacio. Idacio may also increase your risk of certain cancers, including lymphoma. Children and teens taking TNF blockers like Idacio have developed rare, aggressive cancers.
This medicine can cause a severe allergic reaction with fever, rash, and organ problems. Stop taking gabapentin and get medical help right away if you have trouble breathing or swelling of your face, lips, tongue, or throat. Do not drive or operate heavy machinery until you know how gabapentin affects you. Do not stop taking gabapentin suddenly, as this may increase seizures. Gabapentin may cause suicidal thoughts or actions. Watch for changes in mood or behavior. Using gabapentin with opioid medicines can cause very slow breathing, sedation, and death. Children ages 3 to 12 may have new or worsening behavior problems.
Tell your doctor if you are pregnant or plan to become pregnant. Idacio can cross the placenta and may affect your baby's immune system. Talk to your doctor about vaccines for your baby if you took Idacio during pregnancy.
Gabapentin may cause harm to an unborn baby based on animal studies. If you are pregnant or plan to become pregnant, talk to your doctor. Gabapentin passes into breast milk. The effects on a nursing baby are not known.
Also Compare, Nearby Drugs
Compare adalimumab with
Compare gabapentin with
How to Read This adalimumab vs gabapentin Comparison
adalimumab is classified in the TNF-Alpha Inhibitor (Biologic) drug class, while gabapentin sits within the Anticonvulsant / Nerve Pain Agent class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, adalimumab has 219,036 submissions while gabapentin has 101,828. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for adalimumab or gabapentin.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.